Royalty Pharma plc (RPRX) Stock

About Royalty Pharma plc

Royalty Pharma plc is led by CEO Pablo Legorreta, employs 75 people, headquartered in New York, US, publicly traded since 2020.

Royalty Pharma plc (RPRX) stock trades at $63.86 with a market capitalization of $28.44B. The stock is valued at a price-to-earnings (P/E) ratio of 24.15, price-to-book of 3.79, price-to-sales of 10.18. Over the past 52 weeks the stock has ranged between $35.23 and $64.38, and currently trades at or near its 52-week high. It pays a dividend yielding 1.61%.

On profitability, Royalty Pharma plc generates a return on equity (ROE) of 12.25%, return on capital employed of 8.24%, an operating margin of 1.00%, a net profit margin of 32.15%.

In its most recent fiscal year, Royalty Pharma plc reported annual revenue of $2.4B, net profit of $771.0M. Over the last 5 fiscal years, revenue grew at an average annual rate of 2.3%, and net profit declined at an average annual rate of 4.6%.

The balance sheet shows a debt-to-equity ratio of 1.31, a current ratio of 2.66, total assets of $19.6B, $619.0M in cash and equivalents.

RPRX has an average daily trading volume of 3,097,558 shares, a beta of 0.43 (historically less volatile than the overall market).

Royalty Pharma plc by the numbers, 2016–2025

Between 2016 and 2025 Royalty Pharma plc reported revenue of $1.9B rising to $2.4B, a change of +26.7% across 10 years. Compounded, revenue has grown 2.3% a year over five years, 2.1% over three, 5.0% over the last twelve months. Net profit rose to $771.0M.

Operating margin went from 38.5% in 2016 to 65.6% in 2025, a gain of 27.1 percentage points. The most recent net margin is 32.15%. On a trailing twelve-month basis to Jun '26, revenue is $2.5B and net profit $815.0M.

Borrowings rose from $5.9B to $9.0B, cash from operations was $2.5B in the latest year, positive in 9 of the last 10.

Return on equity has averaged 10.6% over five years, and was 11.9% in the most recent year.

The share price itself has compounded at 7.7% a year over five years, 17.5% over three, 58.7% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Royalty Pharma plc (RPRX) — frequently asked questions